-
Alcaraz stunned in Paris Masters opener by Britain's Norrie
-
Dortmund knock Frankfurt out of German Cup on penalties
-
Napoli three points clear at Serie A summit after win at Lecce
-
Putellas scores again to lead Spain into UEFA women's Nations League final
-
Uber partners with Nvidia to deploy 100,000 robotaxis
-
New danger for hurricane-hit Jamaica: wandering crocodiles
-
Trump's granddaughter set to play in LPGA event
-
Depleted South Africa thump sloppy Pakistan in first T20I
-
Apple ordered to pay French operators 39 mn euros over iPhone sales
-
At least 64 killed in Rio drug raid
-
Fears of mass atrocities after Sudan's El-Fasher falls to paramilitaries
-
US revokes visa for Nigerian Nobel laureate Wole Soyinka
-
England rugby coach Borthwick considering moving Earl to centre
-
French prosecutors seek suspended jail terms in Brigitte Macron cyberbullying case
-
Why are stock markets hitting record highs?
-
O'Neill aims to enjoy unexpected Celtic return
-
At least 18 suspects killed in Rio anti-drug raid: governor
-
Wales captain Morgan proclaims love for Ospreys amid club turmoil
-
Monster Hurricane Melissa makes landfall in Jamaica
-
US kills 14 in strikes on alleged Pacific drug boats
-
Nigerian Nobel laureate Wole Soyinka says US visa revoked
-
Saliba and Martinelli add to Arsenal's injury issues
-
Swiss town hands three artefacts back to South Africa
-
Climate change won't end civilization, says Bill Gates
-
Prop forward Porthen to make South Africa debut against Japan
-
South Africa's Wolvaardt calls for calm in World Cup semis
-
Sinner says 'impossible' to finish year as world number one
-
PSG post record turnover for Champions League-winning campaign
-
Berlin says Rosneft subsidiaries not impacted by US sanctions
-
Historically strong Hurricane Melissa nears landfall in Jamaica
-
Musk launches Grokipedia to rival 'left-biased' Wikipedia
-
Cyberbullying has affected Brigitte Macron's health, says daughter
-
Ford edges out Fin Smith for England fly-half role against Australia
-
Medvedev eases past Munar into second round of Paris Masters
-
Wall Street record rally rolls on
-
India's Iyer 'stable' after lacerated spleen: Suryakumar
-
Chelsea boss Maresca vows to 'protect players' with rotation
-
Howe glad Newcastle kept hold of 'complete package' Osula
-
Giant Hurricane Melissa hours from bullseye hit on Jamaica
-
Amazon cuts staff by 14,000
-
O'Neill insists Celtic return after Rodgers exit only temporary
-
World far off track to meet climate goals: UN
-
UK actress Prunella Scales, TV's Sybil Fawlty, dies at 93
-
Stocks retreat after Wall Street surge
-
European court clears Norway of climate misconduct over oil licences
-
Warnings grow of executions, ethnic cleansing in Sudan's El-Fasher
-
Thousands evacuated in Vietnam after record rain triggers floods
-
Billion hopes as India face formidable Australia in World Cup semis
-
Asian markets cool as Trump hails ties on Japan trip
-
Vietnam city sets national record with 1.7 m rain in 24 hours
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
O.Johnson--AMWN